BlackRock, Inc. 13D and 13G filings for KalVista Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-01-29 3:26 pm Purchase | 2023-12-31 | 13G | KalVista Pharmaceuticals, Inc. KALV | BlackRock Inc. BLK | 2,242,025 6.500% | 669,604 (+42.58%) | Filing |
| 2023-01-06 1:46 pm Purchase | 2022-12-31 | 13G | KalVista Pharmaceuticals, Inc. KALV | BlackRock Inc. BLK | 1,572,421 4.600% | 67,801 (+4.51%) | Filing |
| 2022-01-31 5:49 pm Purchase | 2021-12-31 | 13G | KalVista Pharmaceuticals, Inc. KALV | BlackRock Inc. BLK | 1,504,620 6.100% | 391,240 (+35.14%) | Filing |
| 2021-02-02 2:56 pm Purchase | 2020-12-31 | 13G | KalVista Pharmaceuticals, Inc. KALV | BlackRock Inc. BLK | 1,113,380 6.200% | 1,113,380 (New Position) | Filing |